Recipients Selected by
Annual Award Furthers AMAG’s Continued Commitment to
“We are pleased to double our investment in the Lumara Health Research Grants Program this year and have awarded grants to another group of deserving researchers and clinicians who are leading important research efforts to address preterm birth,” said
The 2015 grant recipients were selected by an independent external review panel of experts in maternal-fetal medicine, obstetrics, neonatal/pediatric health chaired by Dr.
“Historically, investments in clinical research focusing on maternal and neonatal populations have lagged behind other research areas. I believe these grants are an important step forward in supporting clinicians and researchers in advancing our understanding of preterm birth, which is a leading health concern among pregnant women,” said Dr. Saade. “I am pleased to be a part of this important effort by
The external review panel awarded grants to the following investigators:
Kelly Gibson, M.D. (Principal Investigator), a clinical instructor at the Case Western Reserve University School of Medicineand physician in maternal-fetal medicine at MetroHealth Medical Center, Brian Mercer, M.D. (co-investigator) and Edward Chien, M.D. (co-investigator) who are conducting a randomized, placebo-controlled double-blinded trial of indomethacin for tocolysis (the suppression of preterm labor); Jennifer L. Herington, Ph.D. (Principal Investigator), Jeff Reese, M.D. (co-Investigator) and Kelly A. Bennett, M.D. (co-Investigator) at Vanderbilt University School of Medicine, who are researching novel therapeutic inhibitors of uterine contractility for the prevention of preterm labor; Sandra Reznik, M.D., Ph.D. (Principal Investigator), an associate professor in pharmaceutical sciences at St. John’s University in New York City, and the director of perinatal pathology and assistant professor in the departments of pathology and obstetrics and gynecology and women’s health at Montefiore Medical Center/Albert Einstein College of Medicinein the Bronx, NY, and Juliet Mushi, M.D. (co-investigator) who are investigating the anti-inflammatory and potential tocolytic activities of N,N-dimethylacetamide-related compounds using in vitro and ex vivo models; and Molly Stout, M.D., MSCI, an assistant professor in obstetrics and gynecology, maternal-fetal medicine at Washington University School of Medicine in St. Louis, Methodius Tuuli, M.D., M.PH. (co-investigator), George Macones, M.D., MSCE (co-investigator), Heidi Fujiwara, Ph.D. (co-investigator) and Daniel Ory, M.D. (co-investigator) will conduct research on 17-hydroxyprogesterone caproate for preterm birth prevention and the association between its metabolites and efficacy.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to statements regarding the company’s commitment to supporting research focused on improving the health of mothers and babies worldwide and the Company’s belief that these grants are an important step forward in supporting clinicians and researchers in advancing our understanding of preterm birth are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, those identified in AMAG’s
AMAG Pharmaceuticals® is a registered trademark of
AMAG Pharmaceuticals, Inc.Contact: Maryann CiminoManager, Corporate Communications & External Affairs617-498-3375